StockData
Soligenix, Inc. logo

Soligenix, Inc. (SNGX) company profile

SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.28−0.01 (-2.67%)

Close on Nov 17, 2026Market cap $6.11MP/E –Yield –

About Soligenix

Pharmaceutical Preparations, SIC 2834

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare diseases with unmet medical needs. The company operates two primary business segments: Specialized BioTherapeutics and Public Health Solutions. Its biotherapeutics pipeline includes synthetic hypericin treatments, primarily HyBryte for cutaneous T-cell lymphoma and SGX302 for psoriasis, alongside dusquetide formulations for rare inflammatory conditions. Its public health segment concentrates on biodefense medical countermeasures, including ricin toxin and filovirus vaccine candidates that utilize a proprietary heat-stabilization platform. The company's end users encompass patients suffering from rare oncology and inflammatory disorders, as well as government agencies and public defense organizations that support and procure biodefense countermeasures.

The company conducts clinical studies across multiple medical centers throughout the United States and engages in regulatory and development activities in Europe and the United Kingdom. Soligenix maintains its principal executive offices and corporate headquarters in Princeton, New Jersey.

Summary of the business section of Soligenix's latest annual report, written by StockData.

Company profile

Company

Legal name
Soligenix, Inc.
Founded
1987
Headquarters
Princeton, NJ
Address
29 Emmons Drive, Suite B-10 08540
Phone
(609) 538-8200
Employees
14, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Cherry Bekaert LLP, Tampa, Florida

Stock & identifiers

Ticker
SNGX
Exchange
Nasdaq
Shares outstanding
22M, Jul 31, 2026
Public float
$4.59M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-16 reverse, Jun 6, 2024; 1-for-15 reverse, Feb 10, 2023; 1-for-10 reverse, Oct 7, 2016; 1-for-20 reverse, Feb 1, 2012; 1-for-15 reverse, Jun 11, 1997
SEC CIK
812796
CUSIP
834223604
ISIN
US8342236044
FIGI
BBG000FVMHG5
Share class FIGI
BBG001SBZ0D9
LEI
549300MN2EF9LQHLT817
EIN
41-1505029

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, Director15,511
Jonathan L. GuarinoCFO11,000
Oreola DoniniCSO–
Richard StraubeCMO (Consulting)8,000
Diane L. ParksDirector14,940
Anthony Gregg LapointeDirector73,781
Jerome B. ZeldisDirector22,917
Robert J. RubinDirector4,385

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.09M$1.21M$420.55K$1–
FY2024$832.63K$697.45K$366.65K$2–
FY2023$700.48K$531.40K$330.74K$4–
FY2022$711.18K$641.82K$320.64K$33–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Christopher J. Schaber
CEO & President
$559.16K$203.54K$290.42K$36.21K$1.09M+31%
Jonathan Guarino
CFO & Senior VP
$263.72K$71.05K$145.21K$36.21K$516.19K+29%
Oreola Donini
CSO & Senior VP
$322.92K$89.51K$145.21K$4.34K$561.98K+30%
Richard C. Straube
CMO & Senior
$168.96K–$14.52K–$183.48K-32%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed a total of 14 persons, including 1 part-time employee and 13 full-time employees, four of whom are MDs/PhDs.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 12, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 18, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 15, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 15, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 14, 2023Late filingNotification of late filing
Jun 23, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 10, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 24, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 23, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 18, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 23, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 15, 2021DelistingNotice of delisting from exchange (Form 25)
Sep 17, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 27, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 18, 2021Late filingNotification of late filing
Dec 17, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 18, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 31, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 12, 2016ListingRegistration of securities on an exchange (Form 8-A)
Aug 25, 2010Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 20, 2010Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 29, 2009Name changeName changed from DOR BIOPHARMA INC to SOLIGENIX, INC.
Jan 16, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 6, 2006DelistingNotice of delisting from exchange (Form 25)
Apr 20, 2006Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 3, 2006Late filingNotification of late filing
Dec 9, 2005Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 29, 2005Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?